Top Quality Factory Supply B7-33 Peptide H2-Relaxin Gtpl 9321 B7-33 10 Mg

• CAS No.: 910463-68-2
• Variety: Lyophilized Powder
• Feature: Lyophilized Powder
• Usage: Lyophilized Powder
• Status: Lyophilized Powder
• Specification Customization: 10 Mg
• Model NO.: B7-33
• Shelf Life: 3 Year
• Minimum Order Quantity: 20 Vials
• Custom Label: From 100 Vials
• User Group: Adult
• Delivery Time: 2-3 Days
• Packing: Box
• Save: Refrigerate
• Transport Package: Box
• Specification: 10 mg
• Trademark: HUG
• Origin: China

Product Description

B7-33 exibits potent anti-fibrotic effects. It is under active research and investigation as a means of reducing fibrosis in acute and chronic diseases like heart failure, lung inflammation, kidney and more.
In animal studies, B7-33 has reduced fibrosis by roughly 50%, leading to prolonged survival following injury and offering the first new means of treating heart failure in 20 years.
It has been shown to reduce excessive scar formation following cardiac injury. It has also shown promise in the treatment of certain vascular disorders as well as preeclampsia of pregnancy.

B7-33 is a singular chain peptide, a smaller analogous derivative of the endogenous relaxin protein (3). Typically, the relaxin peptide is composed of four components - a signal peptide, B chain, C chain, and COOH terminal. Several studies were conducted initially to replicate these peptide structures, however they resulted as being highly insoluble and inactive. After extensive research, scientists modified the structure by producing B chain and elongating the COOH terminal, thereby forming the first ever soluble analogue - B7-33 peptide - in 2016. (3)

Besides the structural difference, the peptide has some other variations from the endogenous proteins. B7-33 peptide has been suggested to act via pERK pathway instead of the cAMP pathway. H2-relaxin has been suggested to produce antifibrotic potential via cAMP pathway, which may potentially stimulate the formation of tumors in the body. This is a major side effect of the relaxin treatment. (1) Furthermore, the peptide may have a strong affinity towards the RXFP-1 receptors. The peptide appears to bind with these RXFP-1 receptors, stimulates pERK pathway, which then leads to increased synthesis of MMP-2 matrix metalloproteinase chemicals. These chemicals then inhibit the scarring of the tissues and thereby prevent fibrosis. (1)